リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Quantifying the Effects of Medical Examination and Possible Risk Factors against the Incidence of Cervical Cancer in a Low Human Papillomavirus Vaccination Coverage: An Ecological Study in Japan」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Quantifying the Effects of Medical Examination and Possible Risk Factors against the Incidence of Cervical Cancer in a Low Human Papillomavirus Vaccination Coverage: An Ecological Study in Japan

喩 悦銘 広島大学

2022.03.23

概要

Cervical cancer (CC) is one of the most common gynecological malignancies in females,　mainly caused by human papillomavirus (HPV). In countries with lower HPV vaccine coverage, such　as Japan, medical examination may play a key role in decreasing CC incidence. This study aimed to　quantify the effect of medical examination on cervical cancer (CC) incidence in Japan, considering　the effects of possible risk factors. By collecting Japan’s Prefectural data on CC incidence (2013–2017),　incidence of sexually transmitted diseases (STDs; Chlamydia, Herpes, Condyloma, and Gonorrhea;　1993–2012), screening and detailed examination rate against CC (2013–2016), smoking rate (2001–　2013), economic status (disposable income and economic surplus; 2014–2015), and education status　(2015), we analyzed associations among them using Pearson’s correlation coefficients. Additionally,　assuming that the incidence of STDs reflects the frequency of risky sexual behavior at the co-infection　point with HPV, we constructed generalized linear models to predict CC incidence, taking a 5–20-　year time-lag between incidences of STDs and the CC incidence. Against CC incidence, Chlamydia　in females and Gonorrhea in males with a 15-year time-lag showed positive associations, while　Condyloma in both genders with a 15-year time-lag, screening rate, economic status, and smoking　rate showed negative associations. An increase in screening test rate by 10% was estimated to　decrease CC incidence by 9.6%. This means that screening tests decrease CC incidence effectively,　but not drastically, suggesting the need for additional countermeasures for CC prevention.

論文の公開元へ

関連論文

参考文献

1. Walboomers, J.M.; Jacobs, M.V.; Manos, M.M.; Bosch, F.X.; Kummer, J.A.; Shah, K.V.; Snijders, P.J.; Peto, J.; Meijer, C.J.; Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12–19. [CrossRef]

2. Andersson, S.; Safari, H.; Mints, M.; Lewensohn-Fuchs, I.; Gyllensten, U.; Johansson, B. Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br. J. Cancer 2005, 92, 2195–2200. [CrossRef] [PubMed]

3. Rotondo, J.C.; Oton-Gonzalez, L.; Mazziotta, C.; Lanzillotti, C.; Iaquinta, M.R.; Tognon, M.; Martini, F. Simultaneous detection and viral DNA load quantification of different human papillomavirus types in clinical specimens by the high analytical droplet digital PCR method. Front. Microbiol. 2020, 11, 591452. [CrossRef] [PubMed]

4. Waggoner, S.E. Cervical cancer. Lancet 2003, 361, 2217–2225. [CrossRef]

5. Okunade, K.S. Human papillomavirus and cervical cancer. J. Obstet. Gynaecol. 2020, 40, 602–608. [CrossRef]

6. zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342–350. [CrossRef]

7. Bharadwaj, M. A step towards resolving the mystery of HPV vaccination: Breakthrough of cervical cancer. Adv. Cytol. Pathol. 2018, 3, 1. [CrossRef]

8. Janicek, M.F.; Averette, H.E. Cervical cancer: Prevention, diagnosis, and therapeutics. CA Cancer. J. Clin. 2001, 51, 92–114. [CrossRef]

9. World Health Organization. The Immunological Basis for Immunization Series: Module 19: Human Papillomavirus Infection; World Health Organization: Geneva, Switzerland, 2011.

10. Senkomago, V.; Henley, S.J.; Thomas, C.C.; Mix, J.M.; Markowitz, L.E.; Saraiya, M. Human papillomavirus-attributable cancers— United States, 2012–2016. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 724–728. [CrossRef] [PubMed]

11. GARDASIL. Available online: https://www.fda.gov/media/74350/download (accessed on 20 October 2020).

12. GARDASIL 9. Available online: https://www.fda.gov/media/90064/download (accessed on 20 October 2020).

13. Simms, K.T.; Hanley, S.J.B.; Smith, M.A.; Keane, A.; Canfell, K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: A modelling study. Lancet Public Health 2020, 5, e223–e234. [CrossRef]

14. Pharmaceutical Products Interview Form of Cervarix. Available online: https://gskpro.com/content/dam/global/hcpportal/ ja_JP/products-info/cervarix/cervarix-if.pdf (accessed on 20 October 2020).

15. Pharmaceutical Products Interview Form of GARDASIL. Available online: https://www.msdconnect.jp/static/mcijapan/ images/if_gardasil.pdf (accessed on 20 October 2020).

16. Pharmaceutical Products Interview Form of SILGARD 9. Available online: https://www.msdconnect.jp/static/mcijapan/ images/if_silgard9.pdf (accessed on 20 October 2020).

17. Implementation of Revised Part of Immunization Act. Available online: https://www.mhlw.go.jp/stf/shingi/2r98520000033079- att/2r985200000330hr_1.pdf (accessed on 20 October 2020).

18. Tsuda, K.; Yamamoto, K.; Leppold, C.; Tanimoto, T.; Kusumi, E.; Komatsu, T.; Kami, M. Trends of media coverage on human papillomavirus vaccination in Japanese newspapers. Clin. Infect. Dis. 2016, 63, 1634–1638. [CrossRef] [PubMed]

19. Hanley, S.J.; Yoshioka, E.; Ito, Y.; Kishi, R. HPV vaccination crisis in Japan. Lancet 2015, 385, 2571. [CrossRef]

20. Ueda, Y.; Enomoto, T.; Sekine, M.; Egawa-Takata, T.; Morimoto, A.; Kimura, T. Japan’s failure to vaccinate girls against human papillomavirus. Am. J. Obstet. Gynecol. 2015, 212, 405–406. [CrossRef]

21. Anttila, T.; Saikku, P.; Koskela, P.; Bloigu, A.; Dillner, J.; Ikaheimo, I.; Jellum, E.; Lehtinen, M.; Lenner, P.; Hakulinen, T.; et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001, 285, 47–51. [CrossRef]

22. Arnheim Dahlstrom, L.; Andersson, K.; Luostarinen, T.; Thoresen, S.; Ogmundsdottir, H.; Tryggvadottir, L.; Wiklund, F.; Skare, G.B.; Eklund, C.; Sjolin, K.; et al. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer. Cancer Epidemiol. Biomark. Prev. 2011, 20, 2541–2550. [CrossRef]

23. Munoz, N.; Castellsague, X.; Berrington de Gonzalez, A.; Gissmann, L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24 (Suppl. S3), 1–10. [CrossRef]

24. Smith, J.S.; Herrero, R.; Bosetti, C.; Munoz, N.; Bosch, F.X.; Eluf-Neto, J.; Castellsague, X.; Meijer, C.J.; Van den Brule, A.J.; Franceschi, S.; et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 2002, 94, 1604–1613. [CrossRef]

25. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr. Eval. Carcinog. Risks Hum. 2004, 83, 1–1438.

26. Vaccarella, S.; Herrero, R.; Snijders, P.J.; Dai, M.; Thomas, J.O.; Hieu, N.T.; Ferreccio, C.; Matos, E.; Posso, H.; de Sanjose, S.; et al. Smoking and human papillomavirus infection: Pooled analysis of the international agency for research on cancer HPV Prevalence Surveys. Int. J. Epidemiol. 2008, 37, 536–546. [CrossRef]

27. Chuang, L.T.; Temin, S.; Camacho, R.; Duenas-Gonzalez, A.; Feldman, S.; Gultekin, M.; Gupta, V.; Horton, S.; Jacob, G.; Kidd, E.A.; et al. Management and care of women with invasive cervical cancer: American society of clinical oncology resource-stratified clinical practice guideline. J. Glob. Oncol. 2016, 2, 311–340. [CrossRef]

28. Randall, T.C.; Ghebre, R. Challenges in prevention and care delivery for women with cervical cancer in Sub-Saharan Africa. Front. Oncol. 2016, 6, 160. [CrossRef]

29. Parikh, S.; Brennan, P.; Boffetta, P. Meta-analysis of social inequality and the risk of cervical cancer. Int. J. Cancer 2003, 105, 687–691. [CrossRef]

30. Hamashima, C.; Aoki, D.; Miyagi, E.; Saito, E.; Nakayama, T.; Sagawa, M.; Saito, H.; Sobue, T.; Japanese Research Group for Development of Cervical Cancer Screening. The Japanese guideline for cervical cancer screening. Jpn. J. Clin. Oncol. 2010, 40, 485–502. [CrossRef]

31. World Health Organization. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention; World Health Organization: Geneva, Switzerland, 2013.

32. Human Papillomavirus (HPV) and Cervical Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/ human-papillomavirus-(hpv)-and-cervical-cancer (accessed on 16 May 2021).

33. Monitoring of Cancer Incidence in Japan. Available online: https://ganjoho.jp/reg_stat/statistics/brochure/monitoring.html (accessed on 20 October 2020).

34. Cancer Registry and Statistics. Available online: https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00 450173&tstat=000001133323&cycle=7&tclass1=000001133363&tclass2=000001133368&tclass3=000001133369&tclass4val=0 (ac- cessed on 20 October 2020).

35. Annual Report of National Epidemiological Surveillance of Infectious Diseases Program. Available online: https://www.niid.go. jp/niid/ja/idsc/8218-surveillance-nenpou.html (accessed on 20 October 2020).

36. Past Annual Report of National Epidemiological Surveillance of Infectious Diseases Program. Available online: https://www. niid.go.jp/niid/ja/allarticles/surveillance/2270-idwr/nenpou/10116-kako2019.html (accessed on 20 October 2020).

37. Download Page of Statistical Data on Cancer Screening. Available online: https://ganjoho.jp/reg_stat/statistics/stat/screening/ dl_screening.html (accessed on 20 October 2020).

38. System of Social and Demographic Statistics Data Prefectural Basic Data. Available online: https://www.e-stat.go.jp/dbview? sid=0000010112 (accessed on 20 October 2020).

39. Average Economic Surplus by Prefecture (The Difference between Disposable Income and The Average Expenditure). Available online: https://www.mlit.go.jp/policy/shingikai/content/001389727.pdf (accessed on 20 October 2020).

40. Employment Status Survey. Available online: https://www.e-stat.go.jp/stat-search/database?page=1&toukei=00200532 (ac- cessed on 20 October 2020).

41. Summary of Result of Estimate Population. Available online: https://www.e-stat.go.jp/stat-search/files?page=1&layout= datalist&toukei=00200241&tstat=000001039591&cycle=7&tclass1=000001039601&tclass2val=0 (accessed on 20 October 2020).

42. Stekhoven, D.J. Miss Forest: Nonparametric Missing Value Imputation using Random Forest. Bioinformatics 2012, 28, 112–118. [CrossRef]

43. R Development Core Team R. The R Foundation for Statistical Computing; R Development Core Team R: Vienna, Austria, 2020.

44. Ripley, B.D.; Venables, W.N. Modern Applied Statistics with S; Springer: Berlin, Germany, 2002.

45. Harrell, F.E. RMS: Regression Modeling Strategies; Springer: Berlin, Germany, 2020.

46. Akaike, H. A new look at the statistical model identification. IEEE Trans Autom. Control 1974, 19, 716–723. [CrossRef]

47. Franceschi, S.; Smith, J.S.; van den Brule, A.; Herrero, R.; Arslan, A.; Anh, P.T.; Bosch, F.X.; Hieu, N.T.; Matos, E.; Posso, H.; et al. Cervical infection with Chlamydia trachomatis and Neisseria gonorrhoeae in women from ten areas in four continents. A cross-sectional study. Sex. Transm. Dis. 2007, 34, 563–569. [CrossRef]

48. Friis, S.; Kjaer, S.K.; Frisch, M.; Mellemkjaer, L.; Olsen, J.H. Cervical intraepithelial neoplasia, anogenital cancer, and other cancer types in women after hospitalization for condylomata acuminata. J. Infect. Dis. 1997, 175, 743–748. [CrossRef]

49. Furgyik, S. Gonorrhea infection as a risk indicator for cervix cancer. Geburtshilfe Frauenheilkd 1987, 47, 320–323. [CrossRef]

50. Lehtinen, M.; Koskela, P.; Jellum, E.; Bloigu, A.; Anttila, T.; Hallmans, G.; Luukkaala, T.; Thoresen, S.; Youngman, L.; Dillner, J.; et al. Herpes simplex virus and risk of cervical cancer: A longitudinal, nested case-control study in the nordic countries. Am. J. Epidemiol. 2002, 156, 687–692. [CrossRef]

51. Sadan, O.; Bilevsky, E.; Shejter, E.; Levy, T.; Bachar, R.; Yarden, H.; Glezerman, M.; Lurie, S. Occurrence of cervical intraepithelial neoplasia in generally healthy women with exophytic vulvar condyloma acuminata. Infect. Dis. Obstet. Gynecol. 2005, 13, 141–143. [CrossRef]

52. Wallin, K.L.; Wiklund, F.; Luostarinen, T.; Angstrom, T.; Anttila, T.; Bergman, F.; Hallmans, G.; Ikaheimo, I.; Koskela, P.; Lehtinen, M.; et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int. J. Cancer 2002, 101, 371–374. [CrossRef]

53. Svare, E.I.; Kjaer, S.K.; Worm, A.M.; Osterlind, A.; Moi, H.; Christensen, R.B.; Meijer, C.J.; Walboomers, J.M.; van den Brule, A.J. Risk factors for HPV infection in women from sexually transmitted disease clinics: Comparison between two areas with different cervical cancer incidence. Int. J. Cancer 1998, 75, 1–8. [CrossRef]

54. Luostarinen, T.; af Geijersstam, V.; Bjorge, T.; Eklund, C.; Hakama, M.; Hakulinen, T.; Jellum, E.; Koskela, P.; Paavonen, J.; Pukkala, E.; et al. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int. J. Cancer 1999, 80, 818–822. [CrossRef]

55. Naucler, P.; Chen, H.C.; Persson, K.; You, S.L.; Hsieh, C.Y.; Sun, C.A.; Dillner, J.; Chen, C.J. Seroprevalence of human papil- lomaviruses and Chlamydia trachomatis and cervical cancer risk: Nested case-control study. J. Gen. Virol. 2007, 88, 814–822. [CrossRef]

56. Wu, S.; Chen, H. Anti-Condyloma acuminata mechanism of microRNAs-375 modulates HPV in cervical cancer cells via the UBE3A and IGF-1R pathway. Oncol. Lett. 2018, 16, 3241–3247. [CrossRef]

57. Landy, R.; Pesola, F.; Castanon, A.; Sasieni, P. Impact of cervical screening on cervical cancer mortality: Estimation using stage-specific results from a nested case-control study. Br. J. Cancer 2016, 115, 1140–1146. [CrossRef]

58. Landy, R.; Sasieni, P.D.; Mathews, C.; Wiggins, C.L.; Robertson, M.; McDonald, Y.J.; Goldberg, D.W.; Scarinci, I.C.; Cuzick, J.; Wheeler, C.M.; et al. Impact of screening on cervical cancer incidence: A population-based case-control study in the United States. Int. J. Cancer 2020, 147, 887–896. [CrossRef]

59. Sasieni, P.; Castanon, A.; Cuzick, J. Effectiveness of cervical screening with age: Population based case-control study of prospectively recorded data. BMJ 2009, 339, b2968. [CrossRef]

60. Yang, B.; Morrell, S.; Zuo, Y.; Roder, D.; Tracey, E.; Jelfs, P. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women. Cancer Causes Control 2008, 19, 569–576. [CrossRef]

61. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Screening for squamous cervical cancer: Duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br. Med. J. (Clin. Res. Ed.) 1986, 293, 659–664. [CrossRef] [PubMed]

62. About the Screening Test of Cervical Cancer. Available online: https://ganjoho.jp/public/pre_scr/screening/about_scr02.html (accessed on 20 October 2020).

63. National Basic Plan to Promote Cancer Control Program in Japan. Available online: https://www.mhlw.go.jp/stf/seisakunitsuite/ bunya/0000183313.html (accessed on 20 October 2020).

64. Sano, H.; Goto, R.; Hamashima, C. Does lack of resources impair access to breast and cervical cancer screening in Japan? PLoS ONE 2017, 12, e0180819. [CrossRef]

65. Drolet, M.; Benard, E.; Boily, M.C.; Ali, H.; Baandrup, L.; Bauer, H.; Beddows, S.; Brisson, J.; Brotherton, J.M.; Cummings, T.; et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and meta-analysis. Lancet Infect. Dis. 2015, 15, 565–580. [CrossRef]

66. Drolet, M.; Benard, E.; Perez, N.; Brisson, M.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. Lancet 2019, 394, 497–509. [CrossRef]

67. Konno, R.; Konishi, H.; Sauvaget, C.; Ohashi, Y.; Kakizoe, T. Effectiveness of HPV vaccination against high grade cervical lesions in Japan. Vaccine 2018, 36, 7913–7915. [CrossRef] [PubMed]

68. Dalton, S.O.; Schuz, J.; Engholm, G.; Johansen, C.; Kjaer, S.K.; Steding-Jessen, M.; Storm, H.H.; Olsen, J.H. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994-2003: Summary of findings. Eur. J. Cancer 2008, 44, 2074–2085. [CrossRef]

69. Vu, M.; Yu, J.; Awolude, O.A.; Chuang, L. Cervical cancer worldwide. Curr. Probl. Cancer 2018, 42, 457–465. [CrossRef] [PubMed]

70. Lacey, J.V., Jr.; Frisch, M.; Brinton, L.A.; Abbas, F.M.; Barnes, W.A.; Gravitt, P.E.; Greenberg, M.D.; Greene, S.M.; Hadjimichael, O.C.; McGowan, L.; et al. Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). Cancer Causes Control 2001, 12, 153–161. [CrossRef] [PubMed]

71. Sugawara, Y.; Tsuji, I.; Mizoue, T.; Inoue, M.; Sawada, N.; Matsuo, K.; Ito, H.; Naito, M.; Nagata, C.; Kitamura, Y.; et al. Cigarette smoking and cervical cancer risk: An evaluation based on a systematic review and meta-analysis among Japanese women. Jpn. J. Clin. Oncol. 2019, 49, 77–86. [CrossRef]

72. Wei, L.; Griego, A.M.; Chu, M.; Ozbun, M.A. Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis 2014, 35, 2373–2381. [CrossRef]

73. Jakobsen, J.C.; Gluud, C.; Wetterslev, J.; Winkel, P. When and how should multiple imputation be used for handling missing data in randomised clinical trials—A practical guide with flowcharts. BMC Med. Res. Methodol. 2017, 17, 162. [CrossRef]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る